Elizabeth M Sherman

Memorial Healthcare System

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Paula Eckardt

Memorial Healthcare System

Melissa E. Badowski

University of Illinois Chicago

Nathan R. Unger

Gilead Sciences (United States)

Jason J. Schafer

Thomas Jefferson University

Sheila Montalvo

Memorial Health System

Timothy P. Gauthier

Baptist Health South Florida

Marylee V. Worley

Nova Southeastern University

Taylor K. Gill

University Health Care System

Kevin A. Clauson

Lipscomb University

Jennifer Cocohoba

University of California, San Francisco

Cooperative Institutions

Ibero American University

104

Nova Southeastern University

Memorial Healthcare System

University of California, San Francisco

University of North Carolina at Chapel Hill

University of Florida

Harvard University

San Francisco General Hospital

University of Illinois Chicago

Johns Hopkins University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Understanding and Managing Antineoplastic and Antiretroviral Therapy

Oxford University Press eBooks (2017)

Jason J. Schafer Elizabeth M Sherman Taylor K. Gill Jatandra Birney

The use of combination antiretroviral therapy in patients with malignancies is associated with improved HIV and cancer-related outcomes. Combining antiretroviral and antineoplastic therapy is often complicated by significant drug-drug interactions, drug-disease state monitoring interactions and overlapping toxicities. Definitive pharmacokinetic studies evaluating drug interactions between antineoplastics and antiretrovirals are uncommon and clinical judgment must often be used to determine the potential for significant interactions. Adjusting antiretroviral therapy in response to significant drug interactions or overlapping toxicities is often more feasible than modifying antineoplastic protocols.

ANTIRETROVIRAL AGENTS

Antiretroviral drug

Cancer Therapy

10.1093/med/9780190493097.003.0029

Cite

Citations (0)

Active Learning Promotes Understanding of Antimicrobial Stewardship

Elizabeth M Sherman Timothy P. Gauthier Nathan R. Unger

Antimicrobial Stewardship

Stewardship

Source

Cite

Citations (0)

Policy Recommendations to Support Equitable Access to Long-Acting Injectables for Human Immunodeficiency Virus Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association

Clinical Infectious Diseases (2025)

Julia L. Marcus Andrea Weddle Colleen F. Kelley Allison L. Agwu Sheila Montalvo

Abstract Long-acting injectables (LAIs) for HIV prevention and treatment could dramatically improve health outcomes and health equity for people with HIV and those who could benefit from pre-exposure prophylaxis. Despite widespread acceptability and demand by providers and potential users of LAIs, implementation has been extremely limited since the introduction of cabotegravir/rilpivirine, the first LAI for HIV treatment, in January 2021, and long-acting cabotegravir, the first LAI for HIV prevention, in December 2021. We report results of a provider survey, conducted by the HIV Medicine Association, which identified LAI implementation barriers related to health insurance processes, staffing and administrative support, drug costs and acquisition, and access for individuals who are uninsured. We provide policy recommendations to address those barriers and facilitate broad and equitable access to LAIs for HIV prevention and treatment, which will be necessary to achieve the goals of the US Ending the HIV Epidemic initiative.

Staffing

Equity

Expanded access

10.1093/cid/ciae648

Cite

Citations (0)

Guidelines for Establishing Pharmacy Services in Ambulatory Care

Elizabeth M Sherman Kirsten Balano Ogechi Ikediobi

Source

Cite

Citations (0)

HIV Update and Requirement for First License Renewals

Elizabeth M Sherman

Source

Cite

Citations (0)

Iatrogenic Cushing Syndrome Following Lumbar Medial Branch Block in a Patient with HIV on Ritonavir and Darunavir

Pain Management (2021)

Abhinav Mohan Steven Tijmes Jackson Cohen Elizabeth M Sherman Paula Eckardt

We present a case report of a 62-year old female with HIV and chronic facetogenic back pain who underwent bilateral L3-L4 and L4-L5 medial branch nerve blocks using triamcinolone acetonide 80 mg. 2 weeks later she presented to the emergency department with acute anxiety/depression and was discharged with psychiatric follow-up. 2 weeks after this she presented to the outpatient HIV clinic with persistent uncontrolled depression alongside classic cushingoid features (e.g., buffalo hump, moon facies). She was diagnosed with iatrogenic Cushing syndrome caused by a drug-drug interaction between triamcinolone and ritonavir, a protease inhibitor and a CYP3A4 enzyme inhibitor. While the literature describes the interaction of ritonavir with intra-articular/intranasal/epidural triamcinolone, this is the first documented occurrence following a nerve block procedure. Symptoms resolved within 6 months alongside discontinuation of protease inhibitor therapy.Lay abstract We report a 62-year old woman with history of HIV and depression who developed Cushing syndrome, which is a state of steroid excess in the body, after a nerve block procedure for treatment of back pain. Her first symptoms were worsening anxiety and depression, causing her to go to the emergency department. Unfortunately, the relationship to the steroids was not identified at the time. Later, she developed increased fat deposition in her face and upper neck, which is characteristic of Cushing syndrome. The HIV medications responsible for this adverse event were determined to be ritonavir and darunavir, which are classified as protease inhibitors. Her symptoms improved within 6 months in association with discontinuation of ritonavir and darunavir. This is the first known case of Cushing syndrome following a nerve block procedure for back pain, although previous cases have documented this occurrence following other forms of steroid treatments.

Ritonavir

Darunavir

Depression

Back Pain

10.2217/pmt-2020-0101

Cite

Citations (3)

Table of Contents

Clinical Therapeutics (2015)

Richard I. Shader Elizabeth M Sherman Marylee V. Worley Nathan R. Unger Timothy P. Gauthier

Table (database)

10.1016/s0149-2918(15)01036-x

Cite

Citations (0)

HIV Infection Overview

Elizabeth M Sherman Marylee V. Worley

Source

Cite

Citations (0)

Review of Tenofovir/Emtricitabine for HIV Pre-Exposure Prophylaxis in Adolescent Patients

K Vikas Sankar Saboura Mahdavi Elizabeth M Sherman Nathan R. Unger

Emtricitabine

Tenofovir

Pre-exposure prophylaxis

Source

Cite

Citations (0)

Personalizing prevention: Advances in pharmacotherapy for HIV prevention

Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2023)

Marisa Brizzi Elizabeth M Sherman Sarah B Green Diana N. Nowicki Emily N. Drwiega

Abstract The HIV epidemic continues to pose a significant burden on the healthcare system. Although the incidence of annual new infections is decreasing, health disparities persist and most new infections remain concentrated into different racial, ethnic, and minority groups. Pre‐exposure prophylaxis (PrEP), which involves those at high risk of acquiring HIV to take chronic medications to prevent acquisition of the virus, is key to preventing new HIV infections. The purpose of this article is to review medication therapies for PrEP and examine their role in personalizing PrEP in different patient populations. Additionally, new medications currently under development for PrEP are reviewed, as well as treatment as prevention (TasP) and post‐exposure prophylaxis (PEP). There are currently four medications available for PrEP: the oral options of co‐formulated emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) or emtricitabine/tenofovir alafenamide (FTC/TAF); injectable long‐acting cabotegravir (CAB‐LA); and the vaginal ring dapivirine (DPV‐VR). FTC/TAF is not currently indicated for persons at risk for HIV through vaginal sex due to lack of studies, but trials are currently ongoing. DPV‐VR is available in Zimbabwe and South Africa and has been endorsed by the World Health Organization but is not currently available in the United States. Several agents are also in development for use in PrEP: the novel long‐acting injectable lenacapavir, a first‐in‐class capsid inhibitor, which has no cross‐resistance to any existing HIV drug class; the subdermal implant islatravir, a first‐in‐class translocation inhibitor; and VRC01, a broadly neutralizing antibody (bnAb) which has been evaluated in proof‐of‐concept studies that may lead to the development of more potent bnAbs. Overall, PrEP is highly effective at preventing HIV infection in high‐risk populations. Identifying optimal PrEP regimens in different patient populations is complex and must consider patient‐specific factors and medication cost and access considerations. Lastly, providers should consider individual patient preferences with regard to prevention to improve access, retention in care, and adherence.

Emtricitabine

Pre-exposure prophylaxis

Tenofovir alafenamide

Dolutegravir

10.1002/phar.2796

Cite

Citations (4)